This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

5 Nov 2012

Idera Pharmaceuticals' receptor antagonist performs well in preclinical trials

Idera has published encouraging results from pre-clinical studies involving TLR 7, 8 and 9.


Idera Pharmaceuticals has published new data from preclinical studies indicating that inhibiting Toll-like Receptors (TLRs) 7, 8 and 9 not only helps limited inflammatory response, but also suppresses induction of Interleukin 1 beta.

Related News